UNITY Biotechnology Inc.

01/02/2026 | Press release | Distributed by Public on 01/02/2026 08:27

Termination Notice (Form 15-12G)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38470

UNITY BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

124 Washington Street, Suite 101

Foxborough, MA 02035

(508) 543-1720

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)

Rule 12g-4(a)(2)

Rule 12h-3(b)(1)(i)

Rule 12h-3(b)(1)(ii)

Rule 15d-6

Rule 15d-22(b)

Approximate number of holders of record as of the certification or notice date: 39

Pursuant to the requirements of the Securities Exchange Act of 1934, Unity Biotechnology, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Unity Biotechnology, Inc.
Date: January 2, 2026 By: /s/ Craig R. Jalbert
Craig R. Jalbert
President
UNITY Biotechnology Inc. published this content on January 02, 2026, and is solely responsible for the information contained herein. Distributed via Edgar on January 02, 2026 at 14:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]